Tekcapital plc New Technology License (9177R)
14 3월 2016 - 4:00PM
UK Regulatory
TIDMTEK
RNS Number : 9177R
Tekcapital plc
14 March 2016
Tekcapital plc
("Tekcapital" or the "Company")
New Technology License
Acquisition of exclusive license to a patent-pending improvement
for non-invasive glucose testing technology
New technology may replace the need for invasive blood testing
for diabetics
Tekcapital plc (AIM: TEK), an international provider of
technology and intellectual property services, announces it has
acquired the exclusive license to a patent application for the
measurement of glucose in saliva from Arizona State University,
which adds to the Company's portfolio of patents for the
non-invasive measurement of glucose.
The exclusively licensed US patent application 62/288,747
entitled "Saliva glucose measurement devices and methods" describes
a safe, fast and non-invasive method and device to collect and
sample glucose in saliva for both human and companion animals. The
biosensor device allows trace saliva fluid samples from a
biological surface to be obtained for electrochemical analysis and
the subsequent detection of analytes using disposable biosensor
strips. The Directors of Tekcapital believe this breakthrough
technology, if commercially successful, could replace the need for
invasive blood tests repeatedly taken by diabetics.
Market potential
According to the World Health Organization, nearly 350 million
people worldwide have diabetes, with over half of these cases in
China and India. Recent research suggests the global market for
Diabetes Diagnostics is forecast to reach $14.2 billion by 2019(1)
with the principal growth drivers including increasing levels of
diabetes incidence and the ageing of the population.
Diabetes is a chronic disease that occurs either when the
pancreas does not produce enough insulin, a hormone that regulates
blood sugar, or when the body cannot effectively use the insulin it
produces. Hyperglycaemia, or raised blood sugar, is a common effect
of uncontrolled diabetes and over time may lead to serious damage
to many of the body's systems, especially the nerves and blood
vessels. Companion animals, particularly dogs and cats, also have
presented an increasing growth of diabetes cases.
The current standard for self-glucose monitoring technologies,
used throughout the world to measure blood glucose in diabetics, is
to draw a blood sample and place the blood on a strip for insertion
into a glucometer. There is a general dislike of the pain and
inconvenience caused by this method, leading to fewer tests being
performed, which may result in inadequate blood glucose control and
complications from the disease. Furthermore, the testing itself can
also cause blood-borne infection. Dog and cat owners routinely face
challenges in gathering blood samples from their dogs and cats,
running the risk of infection around paws, ears, legs, together
with other areas, often deciding to pay for regular and expensive
visits to veterinary clinics.
Dr. Clifford M. Gross, Executive Chairman of Tekcapital,
commented: "This is a step forward in non-invasive, glucose
measurement. If commercialised successfully, this new technology
could encourage patients and pet owners to measure blood sugar
levels more frequently and without discomfort."
(1) Mordor Intelligence, Diabetes Diagnostics - Global Glucose
Monitoring Devices Market - Industry Analysis and Market Forecast
2014-2020, Published November 2015.
For further information please contact:
+1 305 200 3450
Tekcapital Plc Ext 305
Clifford M. Gross info@tekcapital.com
Allenby Capital Limited (Nominated
Adviser & Joint Broker) +44 (0)20 3328 5656
Jeremy Porter / Alex Brearley
Optiva Securities Limited (Joint +44 (0) 20 3137
Broker) 1904
Jeremy King / Vishal Balasingham jeremy.king@optivasecurities.com
+44 (0) 20 7933
Walbrook PR Ltd 8780
Paul Cornelius / Paul McManus
/ Helen Cresswell tekcapital@walbrookpr.com
Tekcapital plc - The World's Largest University Network for Open
Innovation
Tekcapital helps clients profit from new, university-developed
intellectual properties. With our proprietary discovery search
engine, linked to 4,000+ universities in 160 countries, coupled
with expert scientific review, we provide a turn-key service to
make it easy for clients to find and acquire the IP they need to
create a competitive advantage. Tekcapital plc is listed on the AIM
market of the London Stock Exchange (AIM: symbol TEK) and is
headquartered in Oxford, in the UK. For more information, please
visit www.tekcapital.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCGCGDXSDBBGLD
(END) Dow Jones Newswires
March 14, 2016 03:00 ET (07:00 GMT)
Tekcapital (LSE:TEK)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Tekcapital (LSE:TEK)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024